The PrecivityAD™ test is an innovative new blood test(for amyloid plaques in Alzheimer's) intended for use in patients with cognitive impairment.

With your risk of dementia post stroke your doctor should have this test be a protocol to establish a baseline for you.

If found then your doctor needs to prescribe the dementia prevention protocols that they have already assembled. If s/he doesn't have any call the president and ask when competent people will be hired to create them.  Hopefully in time for your children and grandchildren to use.

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:

The PrecivityAD™ test is an innovative new blood test(for amyloid plaques in Alzheimer's) intended for use in patients with cognitive impairment.

The PrecivityAD™ test is an innovative new blood test intended for use in patients with cognitive impairment. The test aims to help physicians better determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.

The PrecivityAD™ test identifies whether a patient is likely to have amyloid plaques in the brain. The test relies on precise and robust quantitation of the Amyloid Beta 42/40 ratio (Aβ 42/40) and detection of the Apolipoprotein E proteotype (equivalent to ApoE genotype) in blood samples, using C₂N’s proprietary mass spectrometry platform.

The PrecivityAD™ test is intended for use in individuals experiencing memory and thinking issues. The test is only available through an order by a physician.

The test is available in 48 states, the District of Columbia, and Puerto Rico; the exceptions are Maryland and New York, which require individual state processes for CLIA labs. C₂N is working toward obtaining the requisite certifications that will permit the PrecivityAD™ test to be available in these states in the near future. Please periodically refer back to this website or contact C₂N at 1.877.226.3424 for status updates on test availability in these two states. 

Summary of Test and Benefits

Knowing that your symptoms are due to Alzheimer’s can help inform your physician to prescribe specific Alzheimer’s treatments in order to aid in the management of the disease.(This is a problem,you don't want it managed, you want it prevented. DEMAND THAT!) If your symptoms are unlikely due to Alzheimer’s (e.g. a normal test result), your physician can search for other causes, some of which can be treated with different interventions.

Earlier detection provides the opportunity for earlier care options, including clinical trials. Many clinical trials for Alzheimer’s disease are looking for participants who show initial signs of cognitive impairment. You also may be eligible to enroll in clinical trials as a result of the PrecivityAD™ test results.

Researchers at C₂N Diagnostics have found the PrecivityAD™ test results to be an accurate indicator of Alzheimer’s disease pathology among people with memory and thinking issues. The PrecivityAD™ test is easy to administer, does not involve any radiation, and is non-invasive. These features make it more accessible than other diagnostic methods doctors use to evaluate issues with memory and thinking.
Download PDF